About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Georgia | 604 Studies

Clinical Trials Lung CancerGeorgia

Lung Cancer Clinical Trials in Georgia

Find 604 clinical trials for lung cancer near Georgia. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Georgia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 1-20 of 604 trials

TerminatedStudy to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsRociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR)…NCT01526928·Duarte, California and 48 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerThis study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with…NCT02352948·Chandler, Arizona and 200 others

Active not recruitingTHIO Sequenced With Cemiplimab in Advanced NSCLCTHIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®).NCT05208944·Birmingham, Alabama and 39 others

TerminatedMarrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCThe purpose of this study is to determine the safety and efficacy of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil in subjects with locally…NCT04069936·Duarte, California and 9 others

CompletedSorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibThis is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and…NCT00609804·Fort Myers, Florida and 15 others

CompletedA Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung CancerBIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or…NCT02283320·Chandler, Arizona and 31 others

Active not recruitingEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibThe purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of…NCT06120140·Chandler, Arizona and 92 others

CompletedA Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsThis is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy…NCT03849469·Encinitas, California and 27 others

CompletedChemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung CancerThis study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.NCT00686959·Birmingham, Alabama and 132 others

Active not recruitingTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeThis phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in…NCT04929041·Phoenix, Arizona and 168 others

Active not recruitingStudy of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesThis study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK)…NCT05783622·Duarte, California and 17 others

TerminatedTIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyThe purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent…NCT02322281·Bakersfield, California and 79 others

CompletedA Study of DF6002 Alone and in Combination With NivolumabThe purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab…NCT04423029·Orange, California and 31 others

RecruitingLung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerThis screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and…NCT03851445·Birmingham, Alabama and 1228 others

Active not recruitingStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationThis is a phase Ib/II open label study.NCT04699188·Atlanta, Georgia and 37 others

Active not recruitingSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer…NCT06074588·Los Angeles, California and 194 others

CompletedA Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung CancerThe purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).NCT01792479·Goodyear, Arizona and 16 others

Active not recruitingStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsINDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in…NCT05651022·Los Angeles, California and 11 others

Active not recruitingA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsThe purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.NCT06238479·Orlando, Florida and 27 others

TerminatedStudy of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1NCT04795713·Duarte, California and 15 others

Page 1 of 31Next

Other Conditions in Georgia

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma